e-therapeutics CEO Ali Mortazavi on the capital markets in London and his company's computational forward RNAi platform

blonca9
Apr 29, 2024
1 min read

He explains the decision to withdraw e-therapeutics from London AIM and describes the HepNet and GalOmic platforms that have produced the company's pipeline.

Recent Posts

See All

ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R

ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor

ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors

e-therapeutics CEO Ali Mortazavi on the capital markets in London and his company's computational forward RNAi platform

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight